Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693664 | 1.00 | GPR3 (0.53) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL14985883 | 0.82 | GPR3 (0.55) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL15083814 | 0.81 | ALDH1A1 (0.58) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL19988074 | 0.81 | GPR3 (0.53) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL17194216 | 0.81 | GPR3 (0.53) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL16432784 | 0.81 | GPR3 (0.53) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL17904025 | 0.79 | ALDH1A1 (0.56) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL92745 | 0.78 | KMT2A (0.50) | ALDH1A1CYP1A2HPGDHSD17B10KMT2A | |
| SCHEMBL28005447 | 0.78 | ALDH1A1 (0.50) | GPR3ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL19267960 | 0.78 | ALDH1A1 (0.50) | GPR3ALDH1A1CYP1A2HPGDNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122754-B2 | Related substance of linagliptin intermediate and synthesis method thereof | WISDOM PHARMACEUTICAL CO., LTD (CN) | 2024-10-22 | — | — | US | claimed |
| CN-117088665-A | Preparation method of high-performance concrete containing superfine sand | 德州润德混凝土有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-117003705-A | Novel 1,2, 3-triazole compound with anti-tumor effect, and preparation method and application thereof | 北京中医药大学 | 2023-11-07 | — | — | CN | claimed |
| CN-116804013-A | Anti-type 2 diabetes compound and application thereof | 武汉艾默佳华生物科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20230010367-A1 | RELATED SUBSTANCE OF LINAGLIPTIN INTERMEDIATE AND SYNTHESIS METHOD THEREOF | WISDOM PHARMACEUTICAL CO., LTD (CN) | 2023-01-12 | — | — | US | claimed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| WO-2022134488-A1 | RELATED SUBSTANCE OF LINAGLIPTIN INTERMEDIATE AND SYNTHESIS METHOD THEREFOR | 江苏慧聚药业有限公司 | 2022-06-30 | — | — | WO | claimed |
| CN-109705121-B | Preparation method of linagliptin intermediate | 深圳市第二人民医院 | 2022-04-01 | — | — | CN | claimed |
| CN-109761983-B | Preparation method of linagliptin | 深圳市第二人民医院 | 2022-03-04 | — | — | CN | claimed |
| CN-105503872-B | A kind of Li Gelieting impurity and its preparation method and application | 北京普德康利医药科技发展有限公司 | 2017-06-27 | — | — | CN | claimed |
| US-20160304520-A1 | An improved process for preparing Linagliptin and its key Intermediates | WOCKHARDT LTD (IN) | 2016-10-20 | — | — | US | claimed |
| CN-105936634-A | Synthetic method of linagliptin | 赤峰赛林泰药业有限公司 | 2016-09-14 | — | — | CN | claimed |
| CN-105622609-A | Preparation method for linagliptin | SHANGHAI WONDER PHARMACEUTICAL CO LTD | 2016-06-01 | — | — | CN | claimed |
| CN-105503872-A | Linagliptin impurity, and preparation method and application thereof | BEIJING PUDEKANGLI PHARMACEUTICAL TECH DEV CO LTD | 2016-04-20 | — | — | CN | claimed |
| CN-104844602-A | Preparation method of Linagliptin | WEIHAI KAIMEIKE MEDICAL TECHNOLOGY DEV CO LTD | 2015-08-19 | — | — | CN | claimed |
| CN-104844603-A | Simple preparation method of II-type antidiabetic drug linagliptin | UNIV WUHAN TECH | 2015-08-19 | — | — | CN | claimed |
| WO-2015004599-A1 | AN IMPROVED PROCESS FOR PREPARING LINAGLIPTIN AND ITS KEY INTERMEDIATES | WOCKHARDT LIMITED (IN) | 2015-01-15 | — | — | WO | claimed |
| CN-103664893-A | Novel DPP-4 inhibitor, and preparation method and medicinal application thereof | UNIV CHINA PHARMA | 2014-03-26 | — | — | CN | claimed |
| EP-2287164-A1 | Process for the manufacture of chiral 8-(3-aminopiperidin-1-yl)-xanthines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010367-A1 | RELATED SUBSTANCE OF LINAGLIPTIN INTERMEDIATE AND SYNTHESIS METHOD THEREOF | DPP4, DPP9, DPP8 | GPR3 2618/4885ALDH1A1 28/4885CYP1A2 76/4885 |
| US-20160304520-A1 | An improved process for preparing Linagliptin and its key Intermediates | DPP4, LCT, DPP3 | GPR3 3094/4885ALDH1A1 545/4885CYP1A2 663/4885 |
| US-12122754-B2 | Related substance of linagliptin intermediate and synthesis method thereof | DPP4, DPP9, DPP8 | GPR3 2618/4885ALDH1A1 28/4885CYP1A2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.